Krystal Biotech outlines $175M-$195M 2026 non-GAAP opex while targeting 6 data readouts before year-end
Krystal Biotech has projected its non-GAAP operating expenses for 2026 to be between $175 million and $195 million. The company also announced plans to release six data readouts before the end of the year, indicating a significant period of clinical and operational activity.
Dow Soars 600 Points As Oil, Bond Yields Plunge: Krystal Biotech, Morgan Stanley, Marriott In Focus
The Dow Jones Industrial Average surged 600 points due to significant drops in oil prices and bond yields. This market action is highlighted by Krystal Biotech, Morgan Stanley, and Marriott International, which are key stocks to watch during this period. Alissa Coram and Ken Shreve provided analysis on the market's performance.
The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability
Krystal Biotech (KRYS) recently received UK approval for Vyjuvek, its gene therapy, and reported increased profitability in Q1 2026, with net income of US$55.93 million. This market expansion and financial flexibility strengthen the company's position, although the "waviness" of Vyjuvek's revenue due to variable treatment patterns remains a key risk. Analysts have varying outlooks, with some seeing the UK approval as an accelerant and others remaining cautious about sales variability.
Krystal Biotech Inc stock (US5012681064): HC Wainwright confirms Buy as UK clears VYJUVEK
HC Wainwright has reaffirmed its "Buy" rating and a $310 price target for Krystal Biotech Inc. This positive analyst sentiment follows the UK's MHRA granting marketing authorization for Krystal Biotech's gene therapy VYJUVEK to treat dystrophic epidermolysis bullosa (DEB). The approval marks VYJUVEK as the first genetic medicine for DEB in the UK, expanding Krystal Biotech's commercial reach into new markets.
Krystal Biotech gains regulatory approval to sell gene therapy in the United Kingdom
Krystal Biotech has secured regulatory approval in the United Kingdom for its dystrophic epidermolysis bullosa treatment, Vyjuvek gene therapy. This adds to their existing approvals in the United States, European Union, and Japan. The Pittsburgh-based company continues to expand its market reach for the gene therapy.
Krystal Biotech's (KRYS) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright has reaffirmed its "buy" rating on Krystal Biotech (NASDAQ:KRYS) and set a $310 price target, indicating a modest potential upside. The company maintains a "Moderate Buy" consensus rating from analysts, with an average target price of $324.11. Krystal Biotech recently exceeded quarterly expectations, reporting $1.83 EPS against estimated $1.45 and revenue of $116.36 million versus $112.11 million anticipated.
Krystal Biotech receives UK approval for gene therapy VYJUVEK By Investing.com
Krystal Biotech Inc. announced that the UK Medicines and Healthcare products Regulatory Agency has granted marketing authorization for VYJUVEK, a gene therapy for treating wounds in patients with dystrophic epidermolysis bullosa (DEB). This marks the first genetic medicine approved in the UK for DEB, authorized for use from birth, and includes flexible administration options similar to those in the US, EU, and Japan. The approval provides up to 12 years of market exclusivity in the UK and follows previous approvals in other major markets, reflecting the company's strong commercial momentum and financial performance.
Krystal Biotech Price Target Maintained With a $310.00/Share by HC Wainwright & Co.
HC Wainwright & Co. has reiterated its Buy rating for Krystal Biotech (NASDAQ: KRYS) and maintained a price target of $310.00 per share. This indicates continued analyst confidence in the company's stock performance and future prospects.
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
Krystal Biotech announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved VYJUVEK for treating wounds in patients with dystrophic epidermolysis bullosa (DEB) from birth. This marks VYJUVEK as the first genetic medicine approved in the United Kingdom for DEB, designed to correct the root cause of the disease. The approval includes flexible administration options and grants the drug orphan designation with up to 12 years of market exclusivity.
The Bull Case For Krystal Biotech (KRYS) Could Change Following UK Vyjuvek Approval And Rising Profitability
Krystal Biotech (KRYS) has received UK approval for Vyjuvek, its gene therapy for dystrophic epidermolysis bullosa, alongside reporting strong first-quarter 2026 net income of US$55.93 million. This dual development—new market access and rising profitability—is expected to significantly bolster the company's financial flexibility and growth prospects in rare genetic disease treatments. The approval could accelerate optimistic revenue forecasts, though analysts remain cautious about potential revenue fluctuations for Vyjuvek.
First UK genetic medicine for DEB lets some patients treat wounds at home
Krystal Biotech has received marketing authorization from the UK MHRA for VYJUVEK to treat dystrophic epidermolysis bullosa (DEB) in patients with COL7A1 mutations from birth. This marks the first genetic medicine approved in the UK for DEB, allowing for flexible administration at home or in healthcare settings. The approval includes up to 12 years of market exclusivity, with launch timing dependent on reimbursement procedures.
Krystal Biotech, Inc. (KRYS) Stock Analysis: Strong Buy Ratings and Promising 5.38% Upside Potential
Krystal Biotech, Inc. (KRYS) is a Pittsburgh-based biotechnology company specializing in genetic medicines, recognized for its strong growth, innovative pipeline, and robust financial performance. The company’s stock is actively gaining investor attention, backed by bullish analyst ratings and a potential upside of 5.38% according to an average target price of $322.78. Krystal Biotech's flagship product, VYJUVEK, and a promising pipeline with multiple clinical candidates position it as a compelling investment in the biotechnology sector.
Assessing Krystal Biotech (KRYS) Valuation After First Quarter Earnings and EPS Growth
Krystal Biotech (KRYS) reported strong first-quarter earnings with significant EPS growth, leading to a 134.53% shareholder return over the last year. While Simply Wall St's narrative suggests the stock is 2.8% undervalued with a fair value of $315 due to pipeline expansion and projected growth, its high P/E ratio of 40.1x compared to the industry average of 17.2x indicates higher valuation risk. Investors are advised to conduct their own detailed analysis given the mixed sentiment and valuation signals.
Krystal Biotech, Inc. Stock 12‑Month Price Target Raised to $330.56, Implies 6% Upside
Krystal Biotech, Inc.'s average 12-month price target has been increased to $330.56 by 9 analysts, up from $326, with forecasts ranging from $284 to $399 per share. This new target suggests a potential upside of approximately 6% from its May 13 closing price. The consensus rating from 12 covering analysts remains a "Buy," with 11 buy recommendations and 1 hold.
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech recently reported strong earnings, but its profitability was boosted by an unusual tax benefit of US$18m. This tax benefit may have temporarily inflated statutory profit, suggesting the company's underlying earnings power might be lower than reported. Investors are cautioned to consider the sustainability of these earnings without such one-off tax advantages.
Krystal Biotech stock hits all-time high at 315.68 USD
Krystal Biotech (KRYS) stock reached an all-time high of $315.68, with a market capitalization of $9.25 billion, reflecting a 138.49% appreciation over the past year. Despite its strong performance and impressive gross profit margin of 94.17%, InvestingPro analysis suggests the stock is currently overvalued. The company recently reported strong Q1 2026 earnings, exceeding revenue and EPS expectations.
Krystal Biotech stock hits all-time high at 315.68 USD
Krystal Biotech (KRYS) stock reached an all-time high of $315.68, currently trading at $316.53, marking a 138.49% appreciation over the past year. The company's robust market performance is underscored by a $9.25 billion market capitalization and an impressive gross profit margin of 94.17%. While the stock is trading near its 52-week high, InvestingPro analysis suggests it is overvalued relative to its Fair Value despite positive first-quarter earnings and revenue results that surpassed expectations.
There May Be Underlying Issues With The Quality Of Krystal Biotech's (NASDAQ:KRYS) Earnings
Krystal Biotech (NASDAQ:KRYS) reported strong earnings, but a tax benefit of US$18m may be overstating the company's sustainable profit levels. This tax benefit, which boosted statutory profit, is unlikely to be repeated, suggesting that the underlying earnings power might be lower than reported. Investors should consider this factor as the profit result may not be a true reflection of the company's long-term profitability.
Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed?
Krystal Biotech (KRYS) reported strong Q1 2026 earnings, with net income rising to US$55.93 million and EPS at US$1.83. The company also secured FDA approval for at-home use of Vyjuvek, its treatment for dystrophic epidermolysis bullosa. These developments could strengthen the company's investment narrative, though revenue remains heavily reliant on Vyjuvek, and "waviness" in treatment patterns and reimbursement challenges are noted risks.
Krystal Biotech (KRYS) Is Up 6.5% After Vyjuvek-Fueled Q1 Profit Jump And Investor Conference Update
Krystal Biotech (KRYS) saw its stock rise by 6.5% following a strong Q1 2026 profit increase and a positive update at an investor conference. The company reported net income of US$55.93 million, largely driven by its product Vyjuvek, which received FDA approval for at-home administration, broadening treatment options for dystrophic epidermolysis bullosa patients. This performance reinforces the near-term earnings potential of Vyjuvek, though the company acknowledges the concentration risk associated with its reliance on this single product while other pipeline programs mature.
Krystal Biotech (KRYS) Is Up 13.1% After Strong Q1 Earnings And FDA Nod For At-Home Vyjuvek Use – Has The Bull Case Changed?
Krystal Biotech (KRYS) reported strong first-quarter 2026 results, with net income rising to US$55.93 million and EPS of US$1.83. The company also secured FDA approval for at-home administration of Vyjuvek, its treatment for dystrophic epidermolysis bullosa patients. These developments, along with upcoming investor engagements, aim to solidify Krystal Biotech's investment narrative by demonstrating commercial progress and increased flexibility for Vyjuvek treatment, although revenue concentration in a single product remains a near-term risk.
A Look At Krystal Biotech (KRYS) Valuation After Vyjuvek Powered Q1 2026 Earnings Beat
Krystal Biotech (KRYS) has seen increased investor interest following its Q1 2026 earnings beat, driven by Vyjuvek revenue and positive FDA updates. Despite recent share price momentum and strong long-term gains, the stock trades at $296.70 against an average analyst target of $318.22, with a fair value narrative suggesting it's 5.8% undervalued at $315 per share. The valuation is based on an expanding pipeline and favorable healthcare dynamics for genetic therapies, though potential risks exist if Vyjuvek's trajectory or reimbursement efforts face challenges.
Krystal Biotech Q1 earnings & sales beat estimates, pipeline in focus
Krystal Biotech (KRYS) reported Q1 earnings and sales that surpassed analyst expectations due to strong commercial execution and operational efficiency. The company highlighted significant progress in its pipeline, particularly for its lead product Vyjuvek, and ongoing development for other gene therapies.
Krystal Biotech Inc (KRYS) Stock Price, Quote, News & History
This article provides a comprehensive overview of Krystal Biotech Inc (KRYS), including its current stock price, key financial statistics, and recent news. It highlights the company's Q1 earnings, FDA label expansion for Vyjuvek to newborns, and analyst forecasts. The content also lists various valuation metrics and compares KRYS to competitors in the biotechnology sector.
Krystal Biotech CEO to speak May 13 at BofA health care event
Krystal Biotech (NASDAQ: KRYS) announced that its Chairman and CEO, Krish S. Krishnan, will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. He is scheduled for a fireside chat at 11:20 am PT and will also hold investor meetings. A webcast of the presentation will be available on the company's Investors website.
Krystal Biotech (Nasdaq:KRYS) - Stock Analysis
Krystal Biotech (NASDAQ: KRYS) is a commercial-stage biotechnology company that focuses on genetic medicines. The company's stock is currently trading 63.1% below its estimated fair value, with earnings projected to grow by 21.05% annually. Recent Q1 2026 results showed strong performance, with Vyjuvek sales up 32% year-over-year and significant pipeline milestones ahead.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech, Inc. announced its participation in the BofA Securities 2026 Health Care Conference in Las Vegas on May 13, 2026. Krish S. Krishnan, Chairman and CEO, will host investor meetings and a fireside chat, which will be webcast live. The company is a commercial-stage biotechnology firm focused on genetic medicines, with its first product VYJUVEK approved for dystrophic epidermolysis bullosa.
Krystal Biotech to Present at BofA Securities 2026 Health Care Conference
Krystal Biotech, Inc. announced its participation in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and CEO, will lead a fireside chat and investor meetings. A webcast of the presentation will be available on the company's website.
Krystal Biotech, Inc. 2026 Q1 - Results - Earnings Call Presentation (NASDAQ:KRYS) 2026-05-06
Krystal Biotech, Inc. (KRYS) reported strong Q1 2026 earnings, with an EPS of $1.83, surpassing estimates by $0.41, and revenue of $116.36 million, beating expectations by $4.22 million and representing a 31.95% year-over-year increase. The company released a slide deck for its earnings call, providing further details on these results.
Krystal Biotech: A Q1 Earnings Beat With Multiple Catalysts In 2026 & 2027 (NASDAQ:KRYS)
Krystal Biotech delivered strong Q1 2026 results, with Vyjuvek sales increasing 32% year-over-year to $116.4M and gross margin expanding to 95%. The company's robust financial position, with $823M in cash and negligible debt, supports a broad clinical pipeline without dilution risk. With two registrational readouts in 2026 and two more enrolling in 2027, KRYS is positioned for significant pipeline-driven upside beyond its current product, Vyjuvek.
Krystal Biotech stock hits all-time high at 301.99 USD By Investing.com
Krystal Biotech (KRYS) stock has reached an all-time high of $302, demonstrating a 76.81% return over the past year. The company recorded a 94% gross profit margin and 34% revenue growth, with Q1 2026 earnings and revenue surpassing analyst expectations. Despite strong performance, BofA Securities adjusted its price target slightly from $325 to $323, maintaining a Buy rating.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
Krystal Biotech (KRYS) reported first-quarter 2026 earnings and sales that surpassed analyst estimates, driven by strong growth in Vyjuvek sales. The company's lead drug, Vyjuvek, which treats dystrophic epidermolysis bullosa, has expanded its reach with over 695 reimbursement approvals in the U.S. and successful international launches in Germany, France, and Japan. Krystal Biotech is also actively advancing a robust clinical pipeline across various therapeutic areas, including respiratory, ophthalmology, oncology, and aesthetics, with several key study results anticipated in late 2026 and 2027.
Krystal Biotech Q1 Net Margin Of 53.9% Tests Bullish Narrative On Profit Durability
Krystal Biotech reported strong Q1 2026 results with a 53.9% net margin and US$116.4 million in revenue, leading to a discussion between bullish and bearish investor narratives. Bulls emphasize the high profitability and growth potential, while bears point to P/E valuation, R&D costs, and variability in quarterly earnings as potential risks. The article delves into these differing perspectives, weighing the company's financial performance against market expectations and future challenges.
Krystal Biotech Q1 Earnings & Sales Beat Estimates, Pipeline in Focus
Krystal Biotech (KRYS) reported strong first-quarter 2026 results, with EPS of $1.83 and revenues of $116.4 million, both surpassing analyst estimates. The company's lead drug, Vyjuvek, generated significant sales, driven by robust patient uptake and international launches. Krystal Biotech is also advancing a diverse pipeline of genetic medicines in various therapeutic areas, including respiratory, ophthalmology, and oncology.
Krystal Biotech Q1 2026 Earnings Call Transcript
Krystal Biotech reported strong Q1 2026 financial results, with net revenue of $116.4 million, driven by Vyjuvec sales, particularly in Europe and Japan. The company achieved a 95% gross margin and its 11th consecutive quarter of positive EPS. Krystal Biotech is also advancing its pipeline with two registrational study readouts expected in 2026 and two in 2027, along with significant progress in CF and Hailey-Hailey disease programs, while maintaining a robust cash position over $1 billion.
Krystal Biotech, Inc. (NASDAQ:KRYS) Q1 2026 Earnings Call Transcript
Krystal Biotech, Inc. reported strong Q1 2026 earnings, exceeding expectations with a reported EPS of $1.83 against an expectation of $1.45, and global VYJUVEK revenue of $116.4 million. The company highlighted significant progress in the U.S. and international markets for VYJUVEK, and anticipates several registrational study readouts this year and next for its pipeline products addressing conditions like corneal abrasions, neurotropic keratitis, cystic fibrosis, and Hailey-Hailey disease. Krystal Biotech emphasized its robust financial position with over $1 billion in cash and investments, and its strategic focus on internal growth rather than mergers or acquisitions.
What Krystal Biotech (KRYS)'s RMAT Win for KB707 in Lung Cancer Means For Shareholders
Krystal Biotech received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for its lung cancer therapy, KB707, which could accelerate its development and review process. This designation enhances the company's oncology pipeline, adding to its existing genetic medicines platform centered on VYJUVEK. The RMAT status is expected to influence Krystal Biotech's investment narrative, with upcoming presentations at major conferences providing more detailed clinical data.
Krystal Biotech Jumps 5.3% Amid Sector-Wide Rally
Krystal Biotech (KRYS) shares rose 5.3% to $280.02 on Monday, driven by a broad rally in the biotechnology sector. This synchronized movement suggests a sector-wide capital rotation rather than company-specific news. Investors are advised to monitor the sustainability of this rally and the emergence of any specific catalysts for Krystal Biotech.
Transcript : Krystal Biotech, Inc., Q1 2026 Earnings Call, May 04, 2026
This article is a transcript of Krystal Biotech, Inc.'s Q1 2026 Earnings Call held on May 04, 2026. The call discusses the company's financial results for the first quarter ended March 31, 2026. The full transcript content is reserved for subscribers.
Krystal Biotech (KRYS) Reports Strong Q1 Revenue, CEO Highlights Growth Momentum
Krystal Biotech (KRYS) exceeded Q1 revenue expectations, reporting $116.36 million, driven by anticipated results from two upcoming registrational studies and global expansion of its product VYJUVEK. Despite a strong financial standing and high P/E ratio, significant insider selling in the past three months raises questions for investors about the stock's short-term performance. The company's GF Score™ of 47 indicates moderate potential for long-term returns, with strong financial strength but room for improvement in profitability.
Krystal Biotech stock rises over 6% on earnings beat and strong revenue
Krystal Biotech (NASDAQ:KRYS) reported strong first-quarter results, with adjusted earnings per share of $1.83 significantly beating analyst estimates and revenue reaching $116.4 million, a 32% increase year-over-year. The company's lead product, VYJUVEK, generated substantial net revenue and secured numerous reimbursement approvals. Krystal Biotech is also progressing with two registrational studies, with top-line results expected later in 2026, and maintained a strong cash position.
Krystal Biotech reports $116.4M in sales as key eye study fills
Krystal Biotech announced strong first-quarter 2026 financial results, reporting $116.4 million in VYJUVEK net product revenue globally and ending the quarter with $1.0 billion in cash and investments. The company also provided significant clinical updates, including the full enrollment of its KB803 study for corneal abrasions and continued enrollment for its KB801 study for neurotrophic keratitis, with top-line results expected later in 2026 for both. Furthermore, the FDA granted platform technology designation for KB407 and KB111, potentially accelerating future development and regulatory processes.
Krystal Biotech (KRYS) grows VYJUVEK sales 32% and advances late-stage gene therapy pipeline
Krystal Biotech reported strong Q1 2026 financial results, with VYJUVEK gene therapy sales increasing by 32% year-over-year to $116.4 million and net income reaching $55.9 million. The company is advancing its genetic medicine pipeline, with two ophthalmology registrational readouts anticipated in 2026 and FDA platform technology designations granted for KB407 and KB111. Krystal Biotech ended the quarter with a robust cash balance of $1.0 billion, supporting its ongoing commercial and research and development activities.
Strong VYJUVEK sales lift Krystal Biotech (NASDAQ: KRYS) Q1 profit
Krystal Biotech (NASDAQ: KRYS) reported a significant profit increase in Q1 2026, driven by robust sales of its gene therapy VYJUVEK, particularly in Europe and Japan. The company achieved $116.4 million in product revenue and a net income of $55.9 million, with a strong gross margin of 95%. Krystal Biotech maintains a solid balance sheet with $823.4 million in cash and investments, supporting its expanding clinical pipeline in various therapeutic areas.
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q1 Revenue $116.4M, vs. FactSet Est of $112.1M
Krystal Biotech, Inc. (KRYS) reported its Q1 revenue of $116.4 million, surpassing the FactSet estimate of $112.1 million. This financial update indicates a stronger-than-expected performance for the biotechnology company in the first quarter.
What Krystal Biotech (KRYS)'s RMAT Win for KB707 in Lung Cancer Means For Shareholders
Krystal Biotech's KB707, an HSV-based immunotherapy, has received Regenerative Medicine Advanced Therapy (RMAT) designation from the U.S. FDA for advanced non-small cell lung cancer, based on encouraging early clinical data. This designation is expected to enhance FDA guidance and potentially accelerate review, bolstering Krystal's emerging oncology pipeline. While it highlights long-term cancer optionality, the company's near-term focus remains on the commercial performance of VYJUVEK and managing its revenue concentration risk.
Krystal Biotech (KRYS) Q1 2026 Preview: EPS Est. $1.42, Reports May 4
Analysts anticipate Krystal Biotech (NASDAQ:KRYS) to report earnings per share of $1.42 and revenue of $112.1 million for Q1 2026, with the report due on May 4th. Expectations for EPS have declined by 17.0% over the last 90 days, signaling growing caution among analysts. Investors will be closely watching for sustained commercial momentum, profitability margins, and management's commentary on the recent estimate revisions.
Krystal Biotech (KRYS) Q1 2026 Preview: EPS Est. $1.42, Reports May 4
Krystal Biotech (KRYS) is expected to report Q1 2026 earnings per share of $1.42 and revenue of $112.1 million on May 4th. Analyst expectations have seen a recent downward revision, with EPS consensus declining by 2.7% over 30 days and 17.0% over 90 days. Investors will be focused on net margin trends, patient metrics, pipeline updates, and management's commentary on the estimate revisions, given the company's strong profitability in the prior year.
Pictet Asset Management Holding SA Sells 40,336 Shares of Krystal Biotech, Inc. $KRYS
Pictet Asset Management Holding SA reduced its stake in Krystal Biotech, Inc. by 20.5% in the fourth quarter, selling 40,336 shares and retaining 156,568 shares worth approximately $38.6 million. Despite this, other institutions like UBS Group AG significantly increased their positions, with institutional investors now holding 86.29% of the company's stock. Krystal Biotech reported strong Q4 earnings, beating estimates, and analysts maintain a "Moderate Buy" rating with a consensus price target of $326.25.
Krystal Biotech lines up May talks on cystic fibrosis, lung cancer
Krystal Biotech (NASDAQ: KRYS) announced upcoming presentations at scientific conferences in May and June 2026, covering gene therapy vectors for primary ciliary dyskinesia, interim results for their cystic fibrosis treatment, and an inhaled immunotherapy for non-small cell lung cancer. The company will share details at the American Society of Gene & Cell Therapy, American Thoracic Society International Conference, and American Society of Clinical Oncology annual meetings. Presentation materials will be available on Krystal Biotech's investor website after each conference.
